The Time Has Come for This Small Biotech Firm to Grow and Thrive

CytomX Therapeutics
CytomX (CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® technology platform for cancer treatments. CytomX’s Probody therapeutics remain inactive until they are activated by proteases in the tumor microenvironment.  
Why This is Important
By . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.